Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder

NCT01624675 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.

NCT NCT01624675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01624675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder
Lead sponsor
Janssen Pharmaceutical K.K.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2012
Completion date
October 31, 2014
Enrollment
39 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

autistic disorder in children and adolescents